BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

BCRX 10.33 -0.02 (-0.19%)
price chart
Reaction to Confirmed Ebola Case in U.S. � UPDATED
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) was up 5% at $9.78 in the after-hours, but that was after a 6.7% drop to $9.78 in regular trading.
Biocryst Pharmaceuticals Inc. (BCRX) Is Rising After U.S. Ebola Case Confirmed  RTT News
What you need to know before markets open  Financial Post
Related articles »  
BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks'
BioCryst Pharmaceuticals, Inc. announced this morning that their small-molecule, nucleoside analogue, BCX-4430, would be entering a dose ranging efficacy study in non-human primates within the next few weeks.
Hope For Ebola Cure  Bidness ETC
BioCryst expects to begin Ebola study in weeks  Yahoo News
Related articles »  
Strong On High Relative Volume: Biocryst Pharmaceuticals (BCRX)
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Biocryst Pharmaceuticals ...
Related articles »  
Why BioCryst Pharmaceuticals Inc. Shares Soared
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Pharmaceuticals (BCRX) Hereditary Angioedema Trial Positive Results ...  SmallCap Network
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ...  MarketWatch
Related articles »  
BioCryst Pharma Inc (BCRX) Coverage Initiated By JP Morgan With Overweight
BioCryst Pharmaceuticals, Inc. (BCRX) was initiated with a 'Overweight' and it was given a $20.00 price target at JP Morgan (JPM) in a research report issued to clients on Friday.
Notable Analyst Actions: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ...  Financial Wired
Related articles »  
Can BioCryst Pharmaceuticals, Inc. (BCRX) Stop The Ebola Outbreak?
Currently there are no approved vaccines or drugs to treat Ebola. All doctors can do is give patients fluid and try to stop the bleeding that Ebola causes.
Biocryst Pharmaceuticals (BCRX) Highlighted As Today's Perilous Reversal ...  TheStreet.com
BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q2 2014 Results ...  Seeking Alpha (registration)
Related articles »  
Why BioCryst Pharmaceuticals, Inc. Shares Spiked Higher
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biopharmaceutical company that develops drugs to block enzymes involved in the development of various diseases, jumped as much as 15% after announcing that its new drug application for ...
BioCryst Pharmaceuticals, Inc. (BCRX) news: BioCyst Pharma +12% after FDA ...  Seeking Alpha
BioCryst Announces Peramivir NDA Acceptance by the FDA  GlobeNewswire (press release)
Related articles »  
Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
BioCryst And NewLink Surge On Latest US Ebola Case
BioCryst Pharmaceuticals, Inc. (BCRX) surged 14.7% yesterday following news that a nurse, who had been in direct physical contact with Thomas Duncan, had also contracted Ebola.
Small Cap Biotech Game Changers: NewLink Genetics Corp (NASDAQ:NLNK ...  StreetWise Report
Related articles »  
Heavy Early Morning Activity On Biocryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
Related articles »